Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. increased its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 20.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,000 shares of the company’s stock after purchasing an additional 4,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in Repare Therapeutics were worth $83,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of RPTX. Acadian Asset Management LLC raised its position in shares of Repare Therapeutics by 212.1% during the 2nd quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after buying an additional 284,036 shares in the last quarter. Blue Owl Capital Holdings LP raised its holdings in Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after purchasing an additional 250,000 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Repare Therapeutics by 428.4% during the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after purchasing an additional 115,916 shares in the last quarter. Renaissance Technologies LLC lifted its position in Repare Therapeutics by 30.7% in the second quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock worth $1,514,000 after purchasing an additional 107,700 shares during the period. Finally, Marshall Wace LLP bought a new position in Repare Therapeutics during the 2nd quarter valued at $273,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on RPTX. Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Monday, September 23rd.

Repare Therapeutics Stock Performance

Shares of NASDAQ:RPTX opened at $3.43 on Thursday. The stock has a market capitalization of $145.60 million, a price-to-earnings ratio of -2.09 and a beta of 0.72. Repare Therapeutics Inc. has a 1-year low of $2.71 and a 1-year high of $8.49. The company has a 50 day moving average price of $3.21 and a 200 day moving average price of $3.39.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.03. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. The business had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $4.02 million. On average, sell-side analysts expect that Repare Therapeutics Inc. will post -2.15 EPS for the current fiscal year.

Repare Therapeutics Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.